{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-22-000062","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.991755+00:00","generated_at":"2026-06-24T01:11:32.410846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q2 revenue down 8% YoY; narrows 2022 guidance","bullets":["Total revenue $10.3M (-8% YoY); Advanced Energy revenue $8.4M (-16% YoY), OEM $1.9M (+55%).","Net loss $5.4M ($0.16 loss per share) vs $4.0M loss in Q2 2021; Adj. EBITDA loss $3.4M vs $2.4M.","Full-year revenue guidance narrowed to $51-56.4M (prev $52.5-59M); net loss guidance widened to $20.1-16.6M.","FDA granted 510(k) clearance for Renuvion Dermal Handpiece (wrinkles) and APR Handpiece (lax skin).","International Advanced Energy generator and handpiece sales fell >45% and >30% YoY respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-22-000062","json":"https://secwatch.observer/filing/0000719135-22-000062.json","markdown":"https://secwatch.observer/filing/0000719135-22-000062.md","text":"https://secwatch.observer/filing/0000719135-22-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000062/0000719135-22-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000062/apyx-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:11:32.410846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}